Knockdown of YKL‐40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer
Authors:
- 9 September 2021
- journal article
- research article
- Published by Wiley in Cell Biology International
- Vol. 45 (12) , 2557-2566
Abstract
Studies have demonstrated that small interfering RNA (siRNA) targeting YKL‐40 (siYKL‐40) inhibits the proliferation, migration, invasion, and induces antiapoptotic abilities of endometrial cancer (EC) HEC‐1A cells. However, its effect on angiogenesis is unclear. The present study aimed to investigate the role of YKL‐40 in endometrial cancer and the related molecular mechanisms. YKL‐40 was knocked down by transfection with siYKL‐40 and the effects on angiogenesis, cell viability, and signaling pathways were investigated. The results showed that siYKL‐40 inhibited VEGFA levels and tube formation in endothelial cells. Additionally, inhibition of YKL‐40 decreased the expression levels of vascular endothelial growth factor (VEGF), phosphorylated vascular endothelial growth factor receptor 2 (pVEGFR2), and phosphorylated extracellular signal‐regulated kinases 1 and 2 (pERK1/2). Furthermore, a nude mice xenograft model of EC showed that siYKL‐40 inhibited tumor growth. Inhibition of YKL‐40 led to suppression of angiogenesis and reduction of microvessel density through VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer cells. Taken together, this study demonstrated novel molecular mechanisms for role of YKL‐40 in EC.Keywords
Funding Information
- National Natural Science Foundation of China (81960464)
This publication has 38 references indexed in Scilit:
- YKL-40 acts as an angiogenic factor to promote tumor angiogenesisFrontiers in Physiology, 2013
- Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markersBritish Journal of Cancer, 2011
- A YKL-40–Neutralizing Antibody Blocks Tumor Angiogenesis and Progression: A Potential Therapeutic Agent in CancersMolecular Cancer Therapeutics, 2011
- Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of GlioblastomaJournal of Biological Chemistry, 2011
- YKL-40 Protein Levels and Clinical Outcome of Human Endometrial CancerJournal of International Medical Research, 2010
- YKL-40, a secreted glycoprotein, promotes tumor angiogenesisOncogene, 2009
- YKL-40 - an emerging biomarker in cardiovascular disease and diabetesCardiovascular Diabetology, 2009
- Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancerGynecologic Oncology, 2007
- Plasma YKL‐40, as a prognostic tumor marker in recurrent ovarian cancerActa Obstetricia et Gynecologica Scandinavica, 2003
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001